Open Access

TAT‑fused IP3R‑derived peptide enhances cisplatin sensitivity of ovarian cancer cells by increasing ER Ca2+ release

  • Authors:
    • Qi Xie
    • Ye Xu
    • Weinan Gao
    • Yong Zhang
    • Jing Su
    • Yanan Liu
    • Yuting Guo
    • Minghan Dou
    • Kebang Hu
    • Liankun Sun
  • View Affiliations

  • Published online on: November 16, 2017     https://doi.org/10.3892/ijmm.2017.3260
  • Pages: 809-817
  • Copyright: © Xie et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Ovarian cancer is the most common gynecological malignancy. At present, cisplatin is used to treat ovarian cancer; however, the development of cisplatin resistance during therapy is a common obstacle to achieving favorable outcomes. Recently, the B‑cell lymphoma 2 (Bcl‑2) BH4 domain has been reported to mediate the prosurvival activity of Bcl‑2 in cancer; however, the involvement of the BH4 domain of Bcl‑2 in the cisplatin resistance of ovarian carcinoma cells is not entirely clear. In this study, we observed the cytoplasmic and mitochondrial levels of Ca2+ by confocal laser microscopy. We also detected cell apoptosis using western blot analysis and flow cytometry. The present study demonstrated that TAT‑fused inositol 1,4,5‑trisphosphate receptor‑derived peptide (TAT‑IDPS), which targets the BH4 domain of Bcl‑2, increased cisplatin‑induced Ca2+ flux from the endoplasmic reticulum (ER) into the cytosol and mitochondria. In addition, TAT‑IDPS increased cisplatin‑induced expression of mitochondrial apoptosis‑associated proteins and ER stress‑associated proteins. These results indicated that TAT‑IDPS may enhance the cytotoxicity of cisplatin toward ovarian carcinoma cells by increasing ER Ca2+ release.
View Figures
View References

Related Articles

Journal Cover

February-2018
Volume 41 Issue 2

Print ISSN: 1107-3756
Online ISSN:1791-244X

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Xie Q, Xu Y, Gao W, Zhang Y, Su J, Liu Y, Guo Y, Dou M, Hu K, Sun L, Sun L, et al: TAT‑fused IP3R‑derived peptide enhances cisplatin sensitivity of ovarian cancer cells by increasing ER Ca2+ release. Int J Mol Med 41: 809-817, 2018.
APA
Xie, Q., Xu, Y., Gao, W., Zhang, Y., Su, J., Liu, Y. ... Sun, L. (2018). TAT‑fused IP3R‑derived peptide enhances cisplatin sensitivity of ovarian cancer cells by increasing ER Ca2+ release. International Journal of Molecular Medicine, 41, 809-817. https://doi.org/10.3892/ijmm.2017.3260
MLA
Xie, Q., Xu, Y., Gao, W., Zhang, Y., Su, J., Liu, Y., Guo, Y., Dou, M., Hu, K., Sun, L."TAT‑fused IP3R‑derived peptide enhances cisplatin sensitivity of ovarian cancer cells by increasing ER Ca2+ release". International Journal of Molecular Medicine 41.2 (2018): 809-817.
Chicago
Xie, Q., Xu, Y., Gao, W., Zhang, Y., Su, J., Liu, Y., Guo, Y., Dou, M., Hu, K., Sun, L."TAT‑fused IP3R‑derived peptide enhances cisplatin sensitivity of ovarian cancer cells by increasing ER Ca2+ release". International Journal of Molecular Medicine 41, no. 2 (2018): 809-817. https://doi.org/10.3892/ijmm.2017.3260